| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
About locoregional recurrence risk after lipofilling in breast cancer patients
|
Semprini, G.
|
|
|
23 |
3 |
p. 802-803
|
artikel
|
| 2 |
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
|
Cognetti, F.
|
|
|
23 |
3 |
p. 695-700
|
artikel
|
| 3 |
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer
|
Verwimp-Hoeks, M.P.A.
|
|
|
23 |
3 |
p. 801-802
|
artikel
|
| 4 |
Association of body mass index in early adulthood and middle age with future site-specific cancer mortality: the Harvard Alumni Health Study
|
Gray, L.
|
|
|
23 |
3 |
p. 754-759
|
artikel
|
| 5 |
Bringing geriatrics into oncology or also oncology into geriatrics?
|
Monfardini, S.
|
|
|
23 |
3 |
p. 801
|
artikel
|
| 6 |
Chemotherapy dose reductions in obese patients with colorectal cancer
|
Chambers, P.
|
|
|
23 |
3 |
p. 748-753
|
artikel
|
| 7 |
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series
|
Roubaud, G.
|
|
|
23 |
3 |
p. 804-805
|
artikel
|
| 8 |
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion
|
Mian, M.
|
|
|
23 |
3 |
p. 729-735
|
artikel
|
| 9 |
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
|
Tibaldi, C.
|
|
|
23 |
3 |
p. 670-677
|
artikel
|
| 10 |
Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis
|
Showalter, T.N.
|
|
|
23 |
3 |
p. 701-706
|
artikel
|
| 11 |
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
|
Sabatier, R.
|
|
|
23 |
3 |
p. 714-721
|
artikel
|
| 12 |
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
|
Ribeiro, J.T.
|
|
|
23 |
3 |
p. 547-555
|
artikel
|
| 13 |
Death causes in breast cancer patients
|
Riihimäki, M.
|
|
|
23 |
3 |
p. 604-610
|
artikel
|
| 14 |
Dietary patterns and the risk of esophageal cancer
|
Bravi, F.
|
|
|
23 |
3 |
p. 765-770
|
artikel
|
| 15 |
Editorial board
|
|
|
|
23 |
3 |
p. ii-iii
|
artikel
|
| 16 |
errata
|
Lara, P.N.
|
|
|
23 |
3 |
p. 810-812
|
artikel
|
| 17 |
errata
|
|
|
|
23 |
3 |
p. 810
|
artikel
|
| 18 |
Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy
|
Shitara, K.
|
|
|
23 |
3 |
p. 659-664
|
artikel
|
| 19 |
Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy
|
Huang, C.-N.
|
|
|
23 |
3 |
p. 707-713
|
artikel
|
| 20 |
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
|
Bui-Nguyen, B.
|
|
|
23 |
3 |
p. 777-784
|
artikel
|
| 21 |
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
|
Pierga, J.-Y.
|
|
|
23 |
3 |
p. 618-624
|
artikel
|
| 22 |
Histology and outcomes of newly detected lung lesions in melanoma patients
|
Smyth, E.C.
|
|
|
23 |
3 |
p. 577-582
|
artikel
|
| 23 |
Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case–control study
|
Cashin, P.H.
|
|
|
23 |
3 |
p. 647-652
|
artikel
|
| 24 |
Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
|
Azambuja, D.
|
|
|
23 |
3 |
p. 736-742
|
artikel
|
| 25 |
Locoregional recurrence risk after lipofilling in breast cancer patients
|
Petit, J.Y.
|
|
|
23 |
3 |
p. 582-588
|
artikel
|
| 26 |
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)
|
Zinzani, P.L.
|
|
|
23 |
3 |
p. 805-807
|
artikel
|
| 27 |
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel †
|
Van Laethem, J.-L.
|
|
|
23 |
3 |
p. 570-576
|
artikel
|
| 28 |
Objective response to sorafenib in advanced clear-cell sarcoma
|
Mir, O.
|
|
|
23 |
3 |
p. 807-809
|
artikel
|
| 29 |
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
|
Lichtman, S.M.
|
|
|
23 |
3 |
p. 632-638
|
artikel
|
| 30 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
|
Verschraegen, C.F.
|
|
|
23 |
3 |
p. 785-790
|
artikel
|
| 31 |
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
|
Gronchi, A.
|
|
|
23 |
3 |
p. 771-776
|
artikel
|
| 32 |
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
|
Campone, M.
|
|
|
23 |
3 |
p. 610-617
|
artikel
|
| 33 |
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer
|
Pera, M.
|
|
|
23 |
3 |
p. 664-670
|
artikel
|
| 34 |
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
|
Gauler, T.C.
|
|
|
23 |
3 |
p. 678-687
|
artikel
|
| 35 |
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
|
Lenihan, D.
|
|
|
23 |
3 |
p. 791-800
|
artikel
|
| 36 |
Power and limits of modern cancer diagnostics: cancer of unknown primary
|
Hemminki, K.
|
|
|
23 |
3 |
p. 760-764
|
artikel
|
| 37 |
Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer
|
Kitagawa, K.
|
|
|
23 |
3 |
p. 743-747
|
artikel
|
| 38 |
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
|
Albanell, J.
|
|
|
23 |
3 |
p. 625-631
|
artikel
|
| 39 |
Pulmonary nodules in patients with melanoma—assume nothing
|
Murphy, F.
|
|
|
23 |
3 |
p. 545-546
|
artikel
|
| 40 |
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
|
Buzdar, A.U.
|
|
|
23 |
3 |
p. 589-597
|
artikel
|
| 41 |
Reply to about locoregional recurrence risk after lipofilling in breast cancer patients
|
Petit, J.-Y.
|
|
|
23 |
3 |
p. 803-804
|
artikel
|
| 42 |
Reply to Rituxan is not associated with Stevens–Johnson syndrome
|
Parise, L.
|
|
|
23 |
3 |
p. 807
|
artikel
|
| 43 |
Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer
|
Li, Z.
|
|
|
23 |
3 |
p. 638-646
|
artikel
|
| 44 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial ‡
|
Zurita, A.J.
|
|
|
23 |
3 |
p. 688-694
|
artikel
|
| 45 |
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix
|
Lieu, C.H.
|
|
|
23 |
3 |
p. 652-658
|
artikel
|
| 46 |
Table of Contents
|
|
|
|
23 |
3 |
p. iv-vi
|
artikel
|
| 47 |
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function
|
Dimopoulos, M.A.
|
|
|
23 |
3 |
p. 722-729
|
artikel
|
| 48 |
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives
|
Sehouli, J.
|
|
|
23 |
3 |
p. 556-562
|
artikel
|
| 49 |
Update on desmoid tumors
|
Escobar, C.
|
|
|
23 |
3 |
p. 562-569
|
artikel
|
| 50 |
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer
|
Gallo, M.
|
|
|
23 |
3 |
p. 597-604
|
artikel
|
Tijdschrift beschrijving